Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$33.11 USD

33.11
1,040,983

+0.26 (0.79%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanghamitra Saha headshot

5 Top-Ranked Stocks Primed for an Earnings Beat

by Sanghamitra Saha

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

Nalak Das headshot

5 Top Picks on Three Key Takeaways From Q2 U.S. GDP

by Nalak Das

A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

by Zacks Equity Research

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

by Zacks Equity Research

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

by Zacks Equity Research

Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark

by Zacks Equity Research

Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.

Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?

by Zacks Equity Research

The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.

Sweta Killa headshot

Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FYC

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Tandem Diabetes (TNDM) closed at $63.76, marking a +1.21% move from the previous day.

Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.

Tandem Diabetes Signs as an Insulin Pump Vendor in Canada

by Zacks Equity Research

Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.

Tandem's Global Growth a Boost, Operating Losses a Bane

by Zacks Equity Research

Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

by Zacks Equity Research

Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.

Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates

by Zacks Equity Research

The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.

Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Tandem, MGM, Meritage, KB Home and Lennar highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Tandem Diabetes Care (TNDM)

by Kevin Cook

FDA approval of its latest smart insulin pump has revived investor faith in shares that once traded above $300

What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

by Zacks Equity Research

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

Tirthankar Chakraborty headshot

4 Dark Horse Stocks Ready to Explode in 2019

by Tirthankar Chakraborty

We highlight a few dark horse stocks that could come up with better-than-expected results this year and won't burn a hole in your pocket